Wuhan Aimin Pharmaceutical

Wuhan Aimin Pharmaceutical is a prominent Chinese pharmaceutical enterprise focused on the development and production of botanical and chemical drugs. Established in 1969, the company has evolved from a military-affiliated factory into a modern high-tech corporation specializing in anti-inflammatory and cardiovascular therapies. It is notably the world's largest production base for Sodium Aescinate, a key treatment for edema and inflammation derived from horse chestnut seeds. The company's portfolio spans across injections, tablets, and topical gels, supported by robust GMP-certified manufacturing capabilities. Wuhan Aimin Pharmaceutical is active in both the domestic Chinese market and international exports, maintaining a strong emphasis on the modernization of traditional Chinese medicine.